Aurinia Pharmaceuticals announced topline data from the Phase 2/3 AUDREY trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES).…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.